Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
State Street SPDR S&P Biotech ETF
(NY:
XBI
)
128.04
-3.53 (-2.68%)
Official Closing Price
Updated: 8:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about State Street SPDR S&P Biotech ETF
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
AskSlim Market Week - Friday, March 18
↗
March 18, 2022
Technical and cycle analysis, and market commentary.
Via
Talk Markets
3 Market ETF Stocks to Buy This Week on Fed Jitters
↗
March 14, 2022
The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over.
Via
InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
↗
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
↗
February 25, 2022
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.
Via
InvestorPlace
3 Desirable Drug Stocks With Very Promising Pipelines
↗
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
XBI Biotech 15% Potential
↗
February 08, 2022
The Biotech Sector ETF had a very nice rally, a bull flag, and ended up having the second half of the move to the upside.
Via
Talk Markets
Top 10 Investment Themes For 2022
↗
December 25, 2021
What are the investment trends going to look like for 2022?
Via
Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
↗
February 14, 2022
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.
Via
Talk Markets
The Dean Martin, “You’re Nobody ‘Till Somebody Loves You” Stock Market (And Sentiment Results)…
↗
February 11, 2022
China Tech (Alibaba) and Biotech have been the two least-loved sectors in recent weeks, but we believe this is changing.
Via
Talk Markets
Small Cap Biotech Stocks: Is it time to start trading?
↗
January 31, 2022
It’s time to trade beaten-up small cap biotech stocks.
Via
Talk Markets
3 Pharma Stocks Yielding Over 3%
↗
January 18, 2022
The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries.
Via
Talk Markets
9 Monster Stock Market Predictions – The Week Of Jan. 17
↗
January 17, 2022
The chart for the SPX is looking more and more like a diamond pattern.
Via
Talk Markets
ETF Battles: Which Biotech Stock ETF Is The Better Choice? - It's IBB Vs. XBI
↗
December 23, 2021
A biotech clash between the iShares Biotechnology ETF and the SPDR S&P Biotech ETF.
Via
Talk Markets
3 Biotech Stocks to Buy That Are Under Severe Pressure
↗
January 13, 2022
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.
Via
InvestorPlace
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
↗
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
Whitney Tilson Names Cannabis ETF 'Favorite Pick For 2022' But Clock Is Ticking To Change US Regulations
↗
January 03, 2022
It was another brutal year for cannabis stock investors in 2021 as the U.S. made very little regulatory progress on cannabis reform measures. Fortu...
Via
Benzinga
Fear & Greed In The Biotech Sector
↗
January 02, 2022
With rates rising, widespread tax-loss selling, and fund manager’s either closing the books for 2021 or just closing down altogether, the market has entered a major risk off phase and biotech stocks...
Via
Talk Markets
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
↗
December 30, 2021
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February.
Via
Talk Markets
The Bear Market Is Already Here – But Not For Dividend Investors
↗
December 22, 2021
While the broad stock market indices remain at near-record levels, there are sectors of the market that have dropped into correction or even bear market territory over recent months.
Via
Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
↗
December 22, 2021
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.
Via
Talk Markets
10 Bargain Stocks to Buy After Falling 30% in 2021
↗
December 20, 2021
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill.
Via
InvestorPlace
Biotech Playbook 2021: No Help From Small Caps In Q4
↗
December 14, 2021
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...
Via
Talk Markets
8 Monster Stock Market Predictions – The Week Of December 13, 2021 Edition
↗
December 12, 2021
Via
Talk Markets
5 Top-Ranked ETFs to Buy At Bargain Prices
↗
December 08, 2021
The beaten-down prices have charged up investors to snap up ETFs on the cheap. Investors could definitely look to these products for outsized gains over the longer term.
Via
Talk Markets
How Did Healthcare Stocks Perform Over This Volatile Month?
↗
December 06, 2021
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%.
Via
Talk Markets
Tuesday Talk: O(micron) - Pow(ell)!
↗
November 30, 2021
As Wall St. investors await the market open Tuesday, futures dive on Omicron concerns as well as anticipation surrounding Yellen and Powell's Senate testimony this morning.
Via
Talk Markets
Stocks Rise On November 29 On Predictable Volatility Crush
↗
November 29, 2021
Stocks jumped on November 29 as volatility came down sharply.
Via
Talk Markets
COVID Is Back Disrupting Markets And Causing More Sector Uncertainty
↗
November 29, 2021
Just when you were having an enjoyable four day weekend cruising along the interminable bull market COVID is back disrupting trends. Healthcare stocks held up reasonably well .Will there be new respect...
Via
Talk Markets
Biotech Stocks are Due for a Rally
↗
November 22, 2021
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Via
Talk Markets
Looking for Growth in Small and Mid Cap Life Science Stocks
↗
November 15, 2021
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
Via
Talk Markets
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.